Insys Therapeutics, Inc. Appoints Andrew G. Long as Chief Financial Officer
July 18 2017 - 6:50AM
Insys Therapeutics, Inc. (NASDAQ:INSY) (“Insys” or “the Company”)
announced today that Andrew G. Long has joined the company as Chief
Financial Officer, effective August 7, 2017.
Andrew G. Long is a seasoned finance executive with
three decades of experience in the life sciences, bio-pharma and
industrial sectors. Mr. Long brings to Insys a diverse set of
experiences, which he honed at companies known for grooming
best-in-class finance talent. His extensive skillset includes:
corporate and operational finance, strategy, supply chain,
information technology, M&A integration and talent acquisition
and development. He most recently served as Senior Vice President
of Global Finance at Patheon, from 2015 to 2017, where he worked
extensively with their operational finance and corporate team
members on a number of initiatives leading up to Patheon’s IPO.
Prior to his role at Patheon, Mr. Long spent nine years providing
management and financial operations expertise as Vice President of
Global Finance for multiple divisions at Thermo Fisher Scientific.
He previously spent five years directing global financial planning,
reporting and analysis activities for the BioScience Division of
Cambrex Corporation. Previously, Mr. Long also spent almost a
decade building his financial expertise in various roles at Abbott
Laboratories.
“Andrew is a results-oriented, progressive leader with extensive
global financial experience. His breadth of experience and
proven record of building organizations and developing talent will
complement the strengths of our senior management team. We look
forward to his leadership and guidance as we focus on growing our
business and developing our pipeline candidates,” stated Saeed
Motahari, President and Chief Executive Officer of Insys.
“I would like to thank Darryl Baker, who has served as our CFO
since the Company’s IPO in 2013, for his commitment and many
contributions to Insys,” added Motahari.
About INSYS Insys Therapeutics is a specialty
pharmaceutical company that develops and commercializes innovative
drugs and novel drug delivery systems of therapeutic molecules that
improve the quality of life of patients. Using proprietary
sublingual spray technology and capabilities to develop
pharmaceutical cannabinoids, INSYS is developing a pipeline of
products intending to address unmet medical needs and the clinical
shortcomings of existing commercial products. INSYS currently
markets one product, SUBSYS® (fentanyl sublingual spray) and has
received approval for the marketing of SYNDROS™ (dronabinol oral
solution), a proprietary, orally administered liquid formulation of
dronabinol. INSYS is committed to developing medications for
potentially treating addiction to opioids, opioid overdose,
epilepsy, and other disease areas with a significant unmet
need.
SUBSYS® and SYNDROS™ are trademarks of Insys Development
Company, Inc., a subsidiary of Insys Therapeutics, Inc.
Forward-Looking Statements
This press release contains forward-looking statements including
regarding our belief that Mr. Long’s breadth of experience and
proven record of building organizations and developing talent will
complement the strengths of our senior management team. These
forward-looking statements are based on management's expectations
and assumptions as of the date of this press release; actual
results may differ materially from those in these forward-looking
statements as a result of various factors, many of which are beyond
our control. These factors include, but are not limited to risk
factors described in our filings with the United States Securities
and Exchange Commission, including those factors discussed under
the caption "Risk Factors" in our Annual Report on Form 10-K for
the year ended December 31, 2016 and subsequent updates that may
occur in our Quarterly Reports on Form 10-Q. Forward-looking
statements speak only as of the date of this press release and we
undertake no obligation to publicly update or revise these
statements, except as may be required by law.
NOTE: All trademarks and registered trademarks are the property
of their respective owners.
Investor Contact:
Lisa M. Wilson
T: 212-452-2793
E: INSYS@insysrx.com
INSYS THERAPEUTICS, INC. (NASDAQ:INSY)
Historical Stock Chart
From Aug 2024 to Sep 2024
INSYS THERAPEUTICS, INC. (NASDAQ:INSY)
Historical Stock Chart
From Sep 2023 to Sep 2024